RPRX vs. SMMT: Royalty Pharma vs. Summit Therapeutics Stock Comparison

Company Profile

Royalty Pharma (RPRX) and Summit Therapeutics (SMMT) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but RPRX is classified in Pharmaceuticals while SMMT is classified in Biotechnology.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Summit Therapeutics (SMMT) reports a negative beta of -1.51, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. Royalty Pharma (RPRX) has a non-negative beta of 0.36.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Summit Therapeutics (SMMT) reports a negative ROE of -220.01%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Royalty Pharma (RPRX) reports 12.09%, ranking against industry peers normally.

Royalty Pharma (RPRX) at 25.70% converts revenue to bottom-line profit above its industry’s benchmark range, while Summit Therapeutics (SMMT) at 0.00% keeps roughly the typical share for its industry.

Royalty Pharma (RPRX) at 81.32% operates in the top operating margin quartile, ahead of Summit Therapeutics (SMMT) at 0.00%, which runs around its industry’s norm.

Profitability Metrics

Growth

Only one side can be read here: Royalty Pharma (RPRX) reports revenue growth of 5.06%, ranked against its industry; Summit Therapeutics (SMMT) has no revenue growth figure this period.

Only one side can be read here: Royalty Pharma (RPRX) reports EPS growth of 23.09%, ranked against its industry; Summit Therapeutics (SMMT) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Summit Therapeutics (SMMT) at 5.99 keeps current ratio within its industry’s typical mid-range, while Royalty Pharma (RPRX) at 1.29 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for RPRX.

Summit Therapeutics (SMMT) at 0.04 carries an industry-typical debt-to-equity mix, while Royalty Pharma (RPRX) at 0.88 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Summit Therapeutics (SMMT) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Royalty Pharma (RPRX) reports a yield of 1.37%, ranking against industry peers normally.

Summit Therapeutics (SMMT) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Royalty Pharma (RPRX) reports a payout of 60.46%, ranking against industry peers normally.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Royalty Pharma (RPRX) trades at 43.99 times trailing earnings, ranked against its peers, while Summit Therapeutics (SMMT) has no P/E ratio this period.

A sales-based read is only available for Royalty Pharma (RPRX), whose P/S ratio of 14.79 ranks against industry peers; Summit Therapeutics (SMMT) reports no figure this period.

Royalty Pharma (RPRX) at 4.39 sits near its industry’s typical P/B ratio, while Summit Therapeutics (SMMT) at 23.13 prices above its benchmark range — SMMT looks rich relative to book.

Valuation Metrics